Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients-Reference-Cited by-同舟云学术

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

Published:2013-05-01 Issue:1 Volume:63 Page:77-85
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Rockstroh Jürgen K.,DeJesus Edwin,Lennox Jeffrey L.,Yazdanpanah Yazdan,Saag Michael S.,Wan Hong,Rodgers Anthony J.,Walker Monica L.,Miller Michael,DiNubile Mark J.,Nguyen Bach-Yen,Teppler Hedy,Leavitt Randi,Sklar Peter

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference12 articles.

1. . Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.;Thompson;JAMA,2012

2. . Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.;Lennox;Lancet,2009

3. . Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.;Lennox;J Acquir Immune Defic Syndr,2010

4. . Long-term treatment with raltegravir or efavirenz combined with tenofoviremtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.;Rockstroh;Clin Infect Dis,2011

5. . Efficacy of raltegravir versus efavirenz when combined with tenofoviremtricitabine in treatment-naive HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.;DeJesus;HIV Clin Trials,2012

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people with HIV with profound immunosuppression;HIV Medicine;2024-08-12

2. Real-world prevalence of integrase inhibitor resistance and virological failure since adoption as guideline-preferred therapy;Drugs in Context;2024-05-16

3. Elevated plasma apolipoprotein E levels in people living with HIV: Associations with biomarkers and HIV-specific risk factors;Atherosclerosis;2024-03

4. Mind bomb 2 limits inflammatory dermatitis in Sharpin mutant mice independently of cell death;PNAS Nexus;2023-12-18

5. Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity;PNAS Nexus;2023-12-18